Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data
Abstract Background Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of ed...
Saved in:
| Main Authors: | Yukari Ogawa, Hiroko Akiyama, Takeshi Horii, Kiyoshi Mihara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Geriatrics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12877-024-05666-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Edaravone's Safety Profile in Acute Ischemic Stroke
by: Laurence K. J. Batino, et al.
Published: (2024-12-01) -
The effect of Edaravone on clinical symptoms and oxidative stress factors in patients with acute ischemic stroke: A clinical trial
by: Mojtaba Khazaei, et al.
Published: (2024-04-01) -
Antioxidant and Apoptotic Effect of Edaravone on Cisplatin-Induced Brain Injury in Rats
by: Ozlem Kara, et al.
Published: (2024-01-01) -
Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
by: Qian Chen, et al.
Published: (2022-04-01) -
Corrigendum: Edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-HNE-associated oxidative stress after subarachnoid hemorrhage
by: Qian Chen, et al.
Published: (2024-12-01)